Takeda Pharmaceutical Company Limited (TAK)
Automate Your Wheel Strategy on TAK
With Tiblio's Option Bot, you can configure your own wheel strategy including TAK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TAK
- Rev/Share 2871.5314
- Book/Share 4372.0238
- PB 0.9713
- Debt/Equity 0.7299
- CurrentRatio 1.2793
- ROIC 0.0428
- MktCap 6704711634698.5
- FreeCF/Share 321.2431
- PFCF 13.1833
- PE 23.1793
- Debt/Assets 0.3466
- DivYield 0.0411
- ROE 0.0404
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | TAK | Morgan Stanley | Equal Weight | Overweight | -- | -- | April 2, 2025 |
News
Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 FY2025 Earnings Call July 30, 2025 6:00 AM ET Company Participants Furuta - Corporate Participant O'Reilly - Corporate Participant Plump - Corporate Participant Weber - Corporate Participant Conference Call Participants Barker - Unidentified Company Kim - Unidentified Company Matsubara - Unidentified Company Muraoka - Unidentified Company Nedelcoyvch - Unidentified Company Ueda - Unidentified Company Wakao - Unidentified Company Yamaguchi - Unidentified Company O'Reilly [inaudible] joining us for FY2025 Q1 earnings announcement by Takeda despite your very busy schedule today. [inaudible] Head of IR.
Read More
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory an.
Read More
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
Published: July 21, 2025 by: Business Wire
Sentiment: Neutral
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo, devices for patients 17 years of age and older that allow HYQVIA® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] to be transferred from vials without using a needle in a home environment or clinical setting.2 The HYQVIA administration process consists of dual vial unit.
Read More
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
In my followup on Takeda Pharmaceutical Co (TAK), I am reaffirming my buy rating from March. Clinical demand in multiple areas, along with an active drug pipeline, could keep driving the top-line despite other big pharma names in this sector. The firm has an attractive balance sheet risk profile, along with proven growth in operating cashflow, but lacks a steady dividend growth long-term or impressive profit margins.
Read More
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-producing neurons in the brain. Orexin agonists are designed to address this underlying orexin deficiency.
Read More
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
Read More
Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2024 Results Conference Call May 8, 2025 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President & Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Julie Kim - President of the U.S. Business Unit & U.S. Country Head Giles Platford - President of the Plasma-Derived Therapies Business Unit Conference Call Participants Hidemaru Yamaguchi - Citi Shinichiro Muraoka - Morgan Stanley Stephen Barker - Jefferies Mike Nedelcovych - TD Cowen Hiroyuki Matsubara - Nomura Securities Seiji Wakao - J.P. Morgan Tony Ren …
Read More
Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO
Published: May 08, 2025 by: CNBC International TV
Sentiment: Positive
Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drugmaker regardless of the global tariff tensions.
Read More
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management. Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rus.
Read More
Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
TAK or DSNKY: Which Is the Better Value Stock Right Now?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Read More
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Value Stocks to Buy for April 30th
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025.
Read More
Best Income Stocks to Buy for April 30th
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025.
Read More
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.
Read More
New Strong Buy Stocks for April 30th
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025.
Read More
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Read More
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Published: April 01, 2025 by: Seeking Alpha
Sentiment: Positive
Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Icotrokinra show strong Phase III results, with potential regulatory approvals and launches by 2026, boosting revenue prospects. Protagonist's financial stability, with a cash runway until 2028, supports a "Strong Buy" rating for high-risk tolerant investors.
Read More
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Read More
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
TAK or DSNKY: Which Is the Better Value Stock Right Now?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Read More
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients. In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1 ZURICH , Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in …
Read More
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Read More
About Takeda Pharmaceutical Company Limited (TAK)
- IPO Date 2010-01-05
- Website https://www.takeda.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Christophe Weber
- Employees 49281